---
title: "20/20 Biolabs to present OneTest webinar outlining Medicare pathway, modeling and reimbursement plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291454602.md"
description: "20/20 Biolabs presented OneTest investor materials outlining a Medicare reimbursement pathway contingent on FDA authorization and CMS appropriateness, potentially starting in 2028. The company highlighted a serial-testing model improving sensitivity and specificity, real-world evidence from over 35,000 firefighters, and an M&A strategy to support scale. These details were furnished via an SEC 8-K filing for a July 1, 2026 webinar."
datetime: "2026-07-01T19:33:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291454602.md)
  - [en](https://longbridge.com/en/news/291454602.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291454602.md)
generator: "portal-rs"
---

# 20/20 Biolabs to present OneTest webinar outlining Medicare pathway, modeling and reimbursement plan

**20/20 Biolabs presented OneTest investor materials highlighting a Medicare reimbursement pathway and modeled sensitivity, specificity and commercialization plans.**

**Key Highlights:**

-   Company furnished investor webinar materials for July 1, 2026; materials are furnished under Item 7.01 and not “filed.”
-   Notes congressional Multi‑Cancer Early Detection Coverage Act creates a Medicare reimbursement pathway starting 2028, contingent on FDA authorization and CMS clinical appropriateness.
-   OneTest serial-testing model shows rising early-stage sensitivity with more frequent tests (e.g., liver 55% → 88%; program specificity 95% → 99%).
-   Company cites over 35,000 U.S. firefighters tested by end of 2026 as real-world evidence and plans to leverage multiple data sources for FDA/CMS totality-of-evidence submissions.
-   Outlines M&A strategy to bolt on businesses with $2–8M revenues to support scale, and projects a royalty pool and revenue upside assuming FDA approval and CMS reimbursement.

Original SEC Filing: 20/20 Biolabs, Inc. \[ AIDX \] - 8-K - Jul. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AIDX.US](https://longbridge.com/en/quote/AIDX.US.md)

## Related News & Research

- [20/20 BioLabs to host investor webinar on East Asia business development tour](https://longbridge.com/en/news/294366646.md)
- [20/20 BioLabs Q1 Revenue Slips; Eyes Q2 Growth From Maryland Firefighter Cancer Screening Program](https://longbridge.com/en/news/287177470.md)
- [CFN Enterprises Delays Quarterly SEC Filing](https://longbridge.com/en/news/296151982.md)
- [Rare Element Resources says no talks held on rumored strategic investment as of Aug. 20, 2026](https://longbridge.com/en/news/296531879.md)
- [Alpha Compute Updates Outstanding Share Count in August 2026 SEC Filing](https://longbridge.com/en/news/296525690.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**